Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
Deng R, Gibiansky L, Lu T, Agarwal P, Ding H, Li X, Kshirsagar S, Lu D, Li C, Girish S, Wang J, Boyer M, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D. Deng R, et al. Among authors: lu t, lu d. Clin Pharmacokinet. 2019 Dec;58(12):1621-1634. doi: 10.1007/s40262-019-00788-8. Clin Pharmacokinet. 2019. PMID: 31209657 Clinical Trial.
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
Deng R, Gibiansky L, Lu T, Li X, Lu D, Li C, Girish S, Wang J, Boyer M, Shankar N, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D. Deng R, et al. Among authors: lu t, lu d. Leuk Lymphoma. 2020 Jan;61(1):56-65. doi: 10.1080/10428194.2019.1657575. Epub 2019 Sep 24. Leuk Lymphoma. 2020. PMID: 31549889 Clinical Trial.
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Shi R, Lu T, Ku G, Ding H, Saito T, Gibiansky L, Agarwal P, Li X, Jin JY, Girish S, Miles D, Li C, Lu D. Shi R, et al. Among authors: lu t, lu d. Cancer Chemother Pharmacol. 2020 Sep;86(3):347-359. doi: 10.1007/s00280-020-04119-8. Epub 2020 Aug 8. Cancer Chemother Pharmacol. 2020. PMID: 32770353 Free PMC article. Clinical Trial.
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
Lu D, Lu T, Shi R, Gibiansky L, Agarwal P, Shemesh CS, Dere RC, Ogbu U, Hirata J, Chanu P, Girish S, Jin JY, Li C, Miles D. Lu D, et al. Among authors: lu t. Pharm Res. 2020 Dec 1;37(12):252. doi: 10.1007/s11095-020-02933-6. Pharm Res. 2020. PMID: 33258982 Free PMC article.
7,455 results